Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response

Cited by (577)

Items 401–500 of 577

1. FXR overexpression alleviates cholestasis via NLRC4 inflammasome suppression and bile acid homeostasis regulation.
   Wenyu Wang, Lin Li, Xia Li, Jia-Qi Chen, Rui Wang, Qi Yang, Yi-Fan Qu, Chang-Yuan Wang, Ting Fu, Qiang Meng · 2025 · Free Radical Biology & Medicine
2. Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
   Kamlesh K. Bhopale, Mukund P. Srinivasan · 2023 · Livers
3. Human Gut Microbiota in Heart Failure: Trying to Unmask an Emerging Organ
   IOANNIS A. PARASKEVAIDIS, Andrew V. Xanthopoulos, Elias Tsougos, Filippos K. Triposkiadis · 2023 · Biomedicines
4. Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro
   Yi Zheng, Jian Zhao, Deyu Miao, Tingting Xu, Liziniu Wang, Changhui Liu, Yong Gao, Lili Yu, Chuangpeng Shen · 2023 · Biomedicine & Pharmacotherapy
5. Microbiome in Behcet's syndrome
   Alessandra Bettiol, Giacomo Emmi, Liying Low, Francesco Sofi, Graham R. Wallace · 2023 · Clinical Immunology
6. Plant Compounds for the Treatment of Diabetes, a Metabolic Disorder: NF-κB as a Therapeutic Target
   Sahukari Ravi, Jyothi Punabaka, Bhasha Shanmugam, Venkata Subbaiah Ganjikunta, Kondeti Ramudu Shanmugam, Sathyavelu Reddy Kesireddy · 2020 · Current Pharmaceutical Design
7. Expression Analysis of ATP-Binding Cassette Transporters ABCB11 and ABCB4 in Primary Sclerosing Cholangitis and Variety of Pediatric and Adult Cholestatic and Noncholestatic Liver Diseases
   Cornelia Thöni, R. Waldherr, J. Scheuerer, S. Schmitteckert, R. Roeth, B. Niesler, E. Cutz, C. Flechtenmacher, B. Goeppert, P. Schirmacher et al. · 2019 · Canadian Journal of Gastroenterology and Hepatology
8. Bile acid receptor agonists in primary biliary cholangitis: Regulation of the cholangiocyte secretome and downstream T cell differentiation
   Rachel E. Etherington, Benjamin John Minford Millar, Barbara A. Innes, David E. Jones, John Andrew Kirby, John G. Brain · 2019 · FASEB BioAdvances
9. GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells
   Xiao-Min Xin · 2014 · World Journal of Gastroenterology
10. How to modulate FXR activity to treat the Metabolic Syndrome
    Janne Prawitt, Sandrine Caron, Bart Staels · 2009 · Drug Discovery Today Disease Mechanisms
11. Bile Acids as Key Mediators of the Gut Microbiota–Immune Axis: Potential Biomarker and Therapeutic Perspectives
    Simone Baldi, Margherita Turrini, Francesco Cei, Marta Menicatti, Gianluca Bartolucci, Amedeo Amedei · 2026 · BioFactors
12. Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials
    Behrad Saeedian, Nastaran Babajani, Tannaz Bagheri, Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji · 2025 · BMC Gastroenterology
13. Hyocholic acid retards renal fibrosis by regulating lipid metabolism and inflammatory response in a sheep model.
    Zeping Zhang, Bo-Yan Zhang, Xian-Zhe Jiang, Yue Yu, Yi-Meng Cui, Hai-Ling Luo, Bing Wang · 2023 · International Immunopharmacology
14. C-Terminal Truncated HBx Facilitates Oncogenesis by Modulating Cell Cycle and Glucose Metabolism in FXR-Deficient Hepatocellular Carcinoma
    Xuejun Wu, Zhengzhong Ni, Tian-Tian Song, Wenya Lv, Yan Chen, Dan-Mei Huang, Yang-Min Xie, Wei-Yi Huang, Yong-Dong Niu · 2023 · International Journal of Molecular Sciences
15. Screening of Biomarkers and Toxicity Mechanisms of Rifampicin-Induced Liver Injury Based on Targeted Bile Acid Metabolomics
    Yong Deng, Xi-Lin Luo, Xin Li, Yi-Qun Xiao, Bin Xu, Huan Tong · 2022 · Frontiers in Pharmacology
16. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
    Yu Yang, Yu Zhao, Wenzhen Li, Yuyao Wu, Xin Wang, Yijie Wang, Ting-Mei Liu, Tinghong Ye, Yongmei Xie, Zhiqiang Cheng et al. · 2020 · European Journal of Medicinal Chemistry
17. Farnesoid X receptor and bile acids regulate vitamin A storage
    A. Saeed, Jing Yang, J. Heegsma, A. Groen, S. V. van Mil, C. Paulusma, Lu Zhou, Bang-Mao Wang, K. Faber · 2019 · Scientific Reports
18. Multi-omic Pathway and Network Analysis to Identify Biomarkers for Hepatocellular Carcinoma
    Megan E. Barefoot, Rency S. Varghese, Yuan Zhou, C. Di Poto, A. Ferrarini, H. Ressom · 2019 · Annual International Conference of the IEEE Engineering in Medicine and Biology Society
19. New therapeutic perspectives in non-alcoholic steatohepatitis.
    J. Ampuero, Y. Sanchez-Torrijos, Virginia Aguilera, F. Bellido, M. Romero-Gómez · 2017 · Gastroenterology & hepatology
20. Oral delivery of chitosan-bilirubin nanoparticles alleviates hepatic inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis
    Afia Tasnim Rahman, Jinyoung Choi, Woojin Kyung, Suyoung Kang, Seojung Lee, Sangyong Jon · 2025 · Biomaterials
21. Gardenia jasminoides Ellis. Polysaccharides Alleviated Cholestatic Liver Injury by Increasing the Production of Butyric Acid and FXR Activation
    Tianming Wang, Tian Tian, Zhenyun Zhu, Su Fang, Lincong Zhang, Xiaotian Peng, Rong Shi, Yuanyuan Li, Jia-Sheng Wu, Yueming Ma · 2024 · Phytotherapy Research
22. A Narrative Review: Immunometabolic Interactions of Host–Gut Microbiota and Botanical Active Ingredients in Gastrointestinal Cancers
    Shanlan Li, Wuwen Feng, Jiaqi Wu, Herong Cui, Yiting Wang, Tianzhen Liang, Jin An, Wanling Chen, Zhuoqian Guo, Haimin Lei · 2024 · International Journal of Molecular Sciences
23. Mid-life plasma proteins associated with late-life prefrailty and frailty: a proteomic analysis
    Fangyu Liu, Jennifer A. Schrack, Jeremy D Walston, Rasika A. Mathias, Beverly Gwen Windham, Morgan Erika Grams, Josef Coresh, Keenan A. Walker · 2024 · GeroScience
24. Delineating the role of nuclear receptors in colorectal cancer, a focused review
    Mukesh Kumar Manickasamy, Sujitha Jayaprakash, Sosmitha Girisa, Aviral Kumar, Hiu Yan Lam, Elena Okina, Huiyan Eng, Mohammed Saeed Alqahtani, Mohamed Abd Elhamid Abbas, Gautam Sethi et al. · 2024 · Discover Oncology
25. Decreased FXR Agonism in the Bile Acid Pool Is Associated with Impaired FXR Signaling in a Pig Model of Pediatric NAFLD
    Magdalena A. Maj, Douglas G. Burrin, Rodrigo Manjarín · 2023 · Biomedicines
26. The Discovery of Obeticholic Acid ( Ocaliva™ ): First‐in‐Class FXR Agonist
    Roberto Pellicciari, Mark Pruzanski, Antimo Gioiello · 2018 · Wiley eBooks
27. Clinical significance of farnesoid X receptor expression in thyroid neoplasia
    Constantinos Giaginis, Nikolaos Tsoukalas, Paraskevi Th. Alexandrou, Gerasimos S. Tsourouflis, Eugene Dana, Ioanna Kassiani Delladetsima, Efstratios Patsouris, Stamatios E Theocharis · 2017 · Future Oncology
28. Impaired bile acid handling and aggravated liver injury in mice expressing a hepatocyte-specific RXRα variant lacking the DNA-Binding Domain
    A. Kosters, J. C. Felix, Moreshwar S. Desai, S. Karpen · 2013 · Journal of Hepatology
29. Hammerhead-type FXR agonists induce an enhancer RNA Fincor that ameliorates nonalcoholic steatohepatitis in mice
    Jinjing Chen, Ruo-Yu Wang, Feng Xiong, Hao Sun, Byron Kemper, Wen-Bo Li, J. Kemper · 2024 · eLife
30. Activation of farnesoid X receptor enhances the efficacy of normothermic machine perfusion in ameliorating liver ischemia-reperfusion injury.
    Qiang Zhao, Xiaobo Wang, Kunpeng Liu, Hong-Hui Chen, Jia Dan, Zebin Zhu, Li-Li Guo, Hua-Di Chen, Wei-Qiang Ju, Dong-Ping Wang et al. · 2024 · American Journal of Transplantation
31. Obeticholic Acid—A Pharmacological and Clinical Review
    Caezaan Keshvani, Jonathan J. Kopel, Hemant Goyal · 2023 · Future Pharmacology
32. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis
    Ki Wung Chung, Ye Eun Cho, Seung-Jin Kim, Seonghwan Hwang · 2022 · Archives of Pharmacal Research
33. Activation of FXR Suppresses Esophageal Squamous Cell Carcinoma Through Antagonizing ERK1/2 Signaling Pathway
    Q. Feng, Hong-Li Zhang, D. Yao, Xiantong Zhang, Wei-Dong Chen, Yan-Dong Wang · 2021 · Cancer Management and Research
34. Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model
    T. Miyazaki, A. Honda, T. Ikegami, T. Iida, Y. Matsuzaki · 2018 · Journal of clinical biochemistry and nutrition
35. FXR activation suppresses NF-κB signaling, proliferation and migration in cervical cancer cells
    Yuan-Qiang Li, Yang-Jian Hong, Huize Shen, Jing Zhou, D. Cesar, J. Eleutério, Motoki Matsuura, Yanyang Liu, Cong Luo, Qing-Lin Li · 2025 · Translational Cancer Research
36. From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension
    Michał Porada, Łukasz Bułdak · 2025 · Metabolites
37. Assessing the Efficacy of Farnesoid X Receptor Agonists in the Management of Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis: Efficacy of Farnesoid X Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: Systematic Review and M
    Jai Kumar, Misha Hasan, Sana Mohsin, T. Nagar, Adeena Jamil, Ali Ahmed, Vamsi Krishna, Sarwan Kumar · 2025 · Clinics And Research in Hepatology and Gastroenterology
38. New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease
    Jinming Zhang, Yixin Li, Yang Liu, Ningning Ma, Shengying Qian, Yingfen Chen, Yajun Duan, Xiaogang Xiang, Yong He · 2024 · Cell & Bioscience
39. Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling
    Rulaiha E. Taylor, Anisha Bhattacharya, Grace Liejun Guo · 2021 · Drug Metabolism and Disposition
40. Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
    Shivaram P. Singh, Prajna Anirvan, Reshu Khandelwal, Sanjaya Kumar Satapathy · 2021 · Journal of Clinical and Translational Hepatology
41. A Novel Combination of Fruits and Vegetables Prevents Diet-Induced Hepatic Steatosis and Metabolic Dysfunction in Mice.
    Weimin Guo, Da-Yong Wu, M. Dao, Lijun Li, E. Lewis, E. Ortega, Heesun Eom, Michael L. Thomas, M. Nikolova-Karakashian, M. Meydani et al. · 2020 · Journal of NutriLife
42. Downregulation of miR-7-5p Inhibits the Tumorigenesis of Esophagus Cancer via Targeting KLF4
    Wo-Da Shi, Jian-Xiang Song, Zheng-Ya Gao, Xing-Chen Liu, Wen-Cai Wang · 2020 · OncoTargets and Therapy
43. Activation of the Nuclear Receptor Fxr Improves Intestinal Cell Tolerance to Ischemia–Reperfusion Injury
    Xuan Wang, Shuo Li, Man Chen, Jing Liu, Rui-Rui Dong, Hua-Min Wang, Shi-Gong Zhu · 2017 · Shock
44. Upregulation of thrombomodulin expression by activation of farnesoid X receptor in vascular endothelial cells.
    Xie He, Zhizhen Xu, Bin Wang, Ying-Ru Zheng, W. Gong, Gang Huang, Li Zhang, Yuan Li, F. He · 2013 · European Journal of Pharmacology
45. Complementary and Alternative Medicine and Cancer Survivorship
    Alyson Louise Huntley, Beverley A. de Valois, Tieraona Low Dog, Francesca Borrelli · 2012 · Evidence-based Complementary and Alternative Medicine
46. Activation of Farnesoid X Receptor Increases the Expression of Cytokine Inducible SH2-Containing Protein in HepG2 Cells
    Zhizhen Xu, Gang Huang, Wei Gong, Yuanyin Zhao, Peng Zhou, Yijun Zeng, Fengtian He · 2012 · Journal of Interferon & Cytokine Research
47. Fish oil feeding reverses hepatomegaly and disrupted hepatic function due to the lack of FXR signaling.
    M. Miyata, Kouhei Shinno, Tomoki Kinoshita, Yuichi Kinoshita, Yoshimasa Sugiura · 2017 · Journal of Toxicological Sciences
48. Molecular Cross-Talk Between Nuclear Receptors and Nuclear Factor-κB
    Ilse M. E. Beck, Guy Haegeman, Karolien De Bosscher · 2010 · Springer eBooks
49. Pharmacology and therapeutics of bile acid synthesis and modification enzymes in metabolic diseases
    Lili Ding, Lihua Jin, Wendong Huang · 2026 · Pharmacological Reviews
50. Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders
    Sosmitha Girisa, B. Aswani, M. Manickasamy, Mangala Hegde, M. Alqahtani, Mohamed Abbas, Gautam Sethi, A. Kunnumakkara · 2025 · Expert opinion on therapeutic targets
51. Targeting farnesoid X receptor as aging intervention therapy
    Lijun Zhang, Jing Yu, Xiaoyan Gao, Yingxuan Yan, Xinyi Wang, Hang Shi, Minglv Fang, Ying Liu, Young‐Bum Kim, Huanhu Zhu et al. · 2025 · Acta Pharmaceutica Sinica B
52. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease
    Jing Wang, Na Yang, Yu Xu · 2024 · The American Journal of Chinese Medicine
53. Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions
    Valentina Cossiga, Maria Guarino, Mario Capasso, Filomena Morisco · 2023 · Cells
54. Advances in understanding the regulatory mechanism of organic solute transporter α-β
    Zhen-Ning Lu, Hongwei He, Na Zhang · 2022 · Life Sciences
55. Partial abrogation of FXR-KNG1 signaling by carboxyl-terminal truncated HBx-C30 in hepatitis B virus-associated hepatocellular carcinoma.
    Yong-Dong Niu, Liming Chen, Man-Peng Wu, Wei-Yi Huang, Xuejun Wu, Dan-Mei Huang, Yang-Min Xie, Gang-Gang Shi · 2020 · Virus Research
56. Cyclosporin A induced toxicity in mouse liver slices is only slightly aggravated by Fxr-deficiency and co-occurs with upregulation of pro-inflammatory genes and downregulation of genes involved in mitochondrial functions
    E. Szalowska, T. Pronk, A. Peijnenburg · 2015 · BMC Genomics
57. Emodin and physcion alleviate cholestatic liver injury by targeting FXR: hepatoprotective components identified in processed Polygonum multiflorum Thunb. using a comprehensive two-dimensional biochromatography system
    Zhihui Li, Yanqiu Gu, Jianbo Yang, Shaozhan Wang, Shengnan Li, Panpan Chen, Ru Yao, Fangbin Liu, Ying Wang, Rong Wang et al. · 2025 · Frontiers in Pharmacology
58. Herpetrione alleviates ANIT-induced cholestatic liver injury by targeting FXR to suppress NF-κB signaling.
    Lin Jing, Yixuan Liao, Hong-Hong Zhan, Qianyu Chen, Xiaodong Wei, Yin-Da Qiu, Fan-Cheng Meng, Zhi-Hua Liao, Min Chen · 2025 · Journal of Ethnopharmacology
59. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
    Angeliki Katsarou, Georgios Tsioulos, Eva N. Kassi, Antonios Chatzigeorgiou · 2024 · HORMONES
60. FXR Friend-ChIPs in the Enterohepatic System
    Vik Meadows, Zhenning Yang, Veronia Basaly, Grace Liejun Guo · 2023 · Seminars in Liver Disease
61. The Bowel-Associated Arthritis–Dermatosis Syndrome (BADAS): A Systematic Review
    I. F. Aromolo, Domenico Simeoli, C. Maronese, A. Altomare, D. Noviello, F. Caprioli, A. Marzano · 2023 · Metabolites
62. Nuclear Receptors and Transcription Factors in Obesity Related Kidney Disease
    Bryce A. Jones, Xiao-Xin X. Wang, K. Myakala, Moshe Levi · 2021 · Seminars in Nephrology
63. Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico
    Ángel Brea, Xavier Pintó, Juan Francisco Ascaso, Mariano Blasco, Ángel Díaz Rodríguez, Pedro González‐Santos, Antonio Hernández‐Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro‐Botet · 2016 · Clínica e Investigación en Arteriosclerosis
64. Inflammation‐associated upregulation of the sulfated steroid transporter Slc10a6 in mouse liver and macrophage cell lines
    Astrid Kosters, Demesew F. Abebe, Julio C. Felix, Paul A. Dawson, Saul J. Karpen · 2015 · Hepatology Research
65. Role of Nuclear Receptors in the Biliary Epithelium
    D. Firrincieli, S. Zúñiga, R. Poupon, C. Housset, N. Chignard · 2011 · Digestive Diseases
66. PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats
    Tarkan Karakan, Mustafa Kerem, Mehmet Cindoruk, Doruk Engin, Murat Alper, Okan Akın · 2013 · The Turkish Journal of Gastroenterology
67. Primary biliary cholangitis. Treatment options in 2025. A narrative review
    Maria Angelara, K. Papachristou, M. Papatheodoridi, N. Nasiri-Ansari, Dimitrios S. Karagiannakis, T. Androutsakos · 2025 · Frontiers in Immunology
68. Metabolic Reprogramming and CD8+ T‐Cell Exhaustion During Chronic HBV Infection
    Haohao Li, Wei-Wei Mu, Alison Zhao, Su Xiao, Chenxin Huo, Huajun Zhao, Hong-Chun Wang, Ronghui Li, Qiu-Ju Han · 2025 · Liver international (Print)
69. Farnesoid X Receptor Agonists as Broad-Acting Antivirals: Evidence from Hepatitis Viruses and Beyond?
    Barnault Romain, Vicente-Navarro Inés, L. Vincent, D. David, Ramière Christophe · 2025 · Antiviral Research
70. Dietary chenodeoxycholic acid inclusion improves carbohydrate utilisation and inflammation of largemouth bass (Micropterus salmoides) partly mediated by the activation of farnesoid X receptor
    Wenfei Li, Ni-He Zhang, Ning Liu, Shi-Wen Chen, Ye Gong, Nai-Song Chen, Song-Lin Li · 2025 · British Journal of Nutrition
71. Farnesoid X Receptor Attenuates the Tumorigenicity of Liver Cancer Stem Cells by Inhibiting STAT3 Phosphorylation
    Wen-Ling Ye, Yang Zhao, Yi-Bo Wang, Ya-Han Wang, Huan Zhang, Feng-Ling Wang, Weidong Chen · 2025 · International Journal of Molecular Sciences
72. Jekyll and Hyde: Nuclear receptors ignite and extinguish hepatic oxidative milieu
    Anushna Sen, S. Anakk · 2021 · Trends in endocrinology and metabolism
73. FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease
    Kiran V.K. Koelfat, Ruben G.J. Visschers, Caroline M.I.M. Hodin, Dirk Rudi de Waart, Wim G. van Gemert, Jack P.M. Cleutjens, Marion J. Gijbels, Ronit Shiri‐Sverdlov, Rajeshwar P. Mookerjee, Kaatje Lenaerts et al. · 2017 · Journal of Clinical and Translational Research
74. On the Pharmacology of Farnesoid X Receptor Agonists: Give me an "A", Like in "Acid"
    Hambruch, Eva, Kinzel, Olaf, Kremoser, Claus · 2016 · Nuclear Receptor Research
75. Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma
    Yongdong Niu, Wen Xie, Wenxin Qin · 2011 · Acta Pharmaceutica Sinica B
76. Microbiota-Derived Metabolites in the Epigenetic Regulation of Redox Homeostasis
    Patricia Mester, Sara Martina Steinmann, Simon Mehler, Martina Müller, Karsten Gülow · 2026 · Antioxidants
77. Farnesoid X Receptor Alleviates Cisplatin‐Induced Kidney Inflammatory Injury by Inhibiting Tlr4/ NF ‐ κB Pathway
    Fangyuan Peng, Jinghan Feng, Xinni Zhang, Ting Ren, Qi Zeng, Qian Sun, Zhouping Zou, Xiaoqiang Ding, Ping Jia · 2025 · Journal of Cellular and Molecular Medicine
78. Farnesoid X Receptor-Mediated Bile Acids Regulation in Cholestasis
    Thamer Abdulla Mohammed, Munaf Hashim Zalzala · 2024 · Indian Journal of Clinical Biochemistry
79. Obeticholic acid ameliorates sepsis-induced renal mitochondrial damage by inhibiting the NF-κb signaling pathway
    Danyang Jing, Jingfeng Liu, Da Qin, Jin Lin, Tian Li, Yu Li, Meili Duan · 2024 · Renal Failure
80. FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses
    Xing Li, Ze-Xiang Zhu, Zhenkun Xia, Bo Xu · 2022 · Journal of Inflammation Research
81. Transcriptional Control of Trpm6 by the Nuclear Receptor FXR
    Eun Young Kim, Jae Man Lee · 2022 · International Journal of Molecular Sciences
82. Synthesis of 12β-Methyl-18-nor-bile Acids
    A. Luxenburger, Lawrence D. Harris, Elizabeth M Ure, Roselis A. Landaeta Aponte, A. D. Woolhouse, S. A. Cameron, C. Ling, R. Piltz, A. Lewis, G. Gainsford et al. · 2021 · ACS Omega
83. Evolving insights in the pathophysiology of complications of cirrhosis: The farnesoid X receptor (FXR) to the rescue?
    W. Laleman, J. Trebicka, L. Verbeke · 2016 · Hepatology
84. Hepatic n-3/n-6 polyunsaturated fatty acid shift improves hepatic steatosis in farnesoid X receptor-null mice
    M. Miyata, Yuichi Kinoshita, Kouhei Shinno, Yoshimasa Sugiura, K. Harada · 2016 · Fisheries Science
85. [Cholestasis and cholestatic liver diseases].
    R. Poupon · 2009 · Gastroentérologie Clinique et Biologique
86. For bugs in bile: the times they are a-changin'.
    E. Stange · 2009 · Gastroenterology
87. Non-Alcoholic Fatty Liver Disease: A 360-degree Overview
    E. Bugianesi · 2020
88. High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics.
    Kong, Defu, Yu, Shihang, Heegsma, Janette, Blokzijl, Tjasso, Qin, Tian, Pan, Yixiao, Blokzijl, Hans, de Meijer, Vincent E., Duan, Yourong, Faber, Klaas Nico et al. · 2026 · Journal of nanobiotechnology
89. An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Jiangshan Shi, Yihui Wen, Lu Wang, Li-Juan Wu, Li Wang, Chen Chen, Hong-Lian Wang, Chang-Ying Zhao · 2026 · Liver international (Print)
90. Mechanistic Analysis of Fisetin in Liver Diseases and Its Potential Therapeutic Application in IFALD—A Review of In Vitro and In Vivo Studies
    Marta Belka, M. Stawny, Michal M. Masternak, V. Krajka-Kuźniak · 2025 · Nutrients
91. Integrated time-course metabolomics and dynamic network analysis reveals stage-specific regulation of arachidonic acid and bile acid metabolism in influenza-associated pneumonitis and enteritis.
    Chen Liu, Qing-Yun Ma, Jing Liu, Qi-Hui Sun, Zhuang-Zhuang Li, Yong Yang, Rong Rong · 2025 · International Immunopharmacology
92. Steroidal scaffold dichotomy: pathogenic role of 7-ketocholesterol versus protective FXR-antagonistic actions of guggulsterone in metabolic regulation.
    Sarvesh Sabarathinam, Nila Ganamurali · 2025 · Steroids
93. Farnesoid X receptor activation alleviates hepatic encephalopathy by improving hepatic ammonia metabolism in murine models
    Wenling Ye, Xiaojie Bai, Yang Zhao, Zhiqun Du, Fang Liu, Yan‐Dong Wang, Wei‐Dong Chen · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
94. Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy
    Yawen Wang, Lei Yang, Qing Xu, Taiyu Liu, H. He, Lisha Liu, Lifang Yin · 2024 · Pharmaceutics
95. Ursodeoxycholic Acid Modulates the Interaction of miR-21 and Farnesoid X Receptor and NF-κB Signaling
    Chi-Yi Peng, Yi‐Chun Liao, Yi‐Chin Yang, Yi-Wen Hung, Lan-Ru Huang, Yen‐Chun Peng · 2024 · Biomedicines
96. Commentary: Can FXR serve as a potential target for COVID-19 prevention?
    J. Pang, Jia-Nuo Feng, W. Ling, Tian-Ru Jin · 2023 · Acta Pharmaceutica Sinica B
97. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease
    Lampros Chrysavgis, Ilias Giannakodimos, A. Chatzigeorgiou, K. Tziomalos, G. Papatheodoridis, E. Cholongitas · 2022 · Expert Review of Gastroenterology & Hepatology
98. Effects of intestine-specific deletion of fibroblast growth factor 15 on alcoholic liver disease development in mice
    B. Kong, Ming-Xing Huang, Rulaiha E. Taylor, D. Rizzolo, Katherine Otersen, Grace L. Guo · 2022 · Liver Research
99. Segmental Bronchial Allergen Challenge Elicits Distinct Metabolic Phenotypes in Allergic Asthma
    Yan-Long Zhu, S. Esnault, Ying Ge, N. Jarjour, A. Brasier · 2022 · Metabolites
100. Synthesis of Novel C/D Ring Modified Bile Acids
     Roselis A. Landaeta Aponte, A. Luxenburger, S. A. Cameron, A. Weymouth-Wilson, R. Furneaux, Lawrence D. Harris, B. Compton · 2022 · Molecules